ARISTO — Aristo Bio-Tech and Lifescience Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeMicro CapNeutral

Annual income statement for Aristo Bio-Tech and Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,672	1,660	2,179	2,451	3,181
Cost of Revenue
Gross Profit	172	189	221	194	226
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	1,636	1,616	2,107	2,382	3,114
Operating Profit	35.9	43.6	71.7	69.2	66.7
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	15	20.4	47.4	54.1	54.7
Provision for Income Taxes
Net Income After Taxes	10.8	14.5	35.6	39	40.6
Net Income Before Extraordinary Items
Net Income	10.8	14.5	35.6	39	40.6
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10.8	14.5	35.6	39	40.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.58	2.11	5.23	5.72	5.97
Dividends per Share